AFT Pharmaceuticals Ltd.

As of March 31, 2026, AFT Pharmaceuticals Ltd. carries a market capitalization of 285.12M, placing it among publicly traded companies globally. Its enterprise value stands at 320.64M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

AFT Pharmaceuticals Ltd.'s next confirmed earnings release is scheduled for November 19, 2026.

As of March 31, 2026, AFT Pharmaceuticals Ltd. has 104.87M shares outstanding.

As of March 31, 2026, AFT Pharmaceuticals Ltd. trades at a trailing price-to-earnings ratio of 23.25. The price-to-sales ratio is 1.36, and the price-to-book ratio stands at 3.11.

As of March 31, 2026, AFT Pharmaceuticals Ltd. trades at an EV/EBITDA multiple of 18.40 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.53 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 22.34 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 320.64M versus a market cap of 285.12M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, AFT Pharmaceuticals Ltd. maintains a current ratio of 2.24, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 49.61, indicating elevated leverage, while an interest coverage ratio of 9.44 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended March 31, 2026, AFT Pharmaceuticals Ltd. posted a return on equity (ROE) of 14.17, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.40 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 7.62, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 11.58, useful for judging operating efficiency across full business cycles. The company generates approximately 1.66M in revenue per employee across its workforce of 126.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.35 indicates how many times AFT Pharmaceuticals Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, AFT Pharmaceuticals Ltd. recorded 6.49M in income tax expense. That works out to an effective tax rate of 35.64, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 18.21M, leaving 12.26M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 21, 2026, AFT Pharmaceuticals Ltd.'s stock has gained approximately 39.08% over the past 52 weeks. The 50-day moving average sits at 3.64, while the 200-day moving average is 3.06.

Over the twelve months ended March 31, 2026, AFT Pharmaceuticals Ltd. generated 209.15M in revenue and converted that into 12.26M in net income, yielding earnings per share of 0.11. EBITDA reached 17.43M, while operating income came in at 14.35M.

As of March 31, 2026, AFT Pharmaceuticals Ltd. holds 8.53M in cash and equivalents against 45.05M in total debt, resulting in a net debt position of 33.59M. Total book value stands at 91.82M, with working capital of 68.44M providing operational flexibility.

These figures cover the twelve months ended March 31, 2026.

Over the twelve months ended March 31, 2026, AFT Pharmaceuticals Ltd. posted a gross margin of 42.61, reflecting its pricing power and cost economics. The operating margin of 6.86 and net profit margin of 5.86 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, AFT Pharmaceuticals Ltd. paid dividends of 0.01 per share. The dividend payout ratio of 14.05 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -2.57, meaning AFT Pharmaceuticals Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of March 31, 2026, AFT Pharmaceuticals Ltd. has an Altman Z-Score of 4.86, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.